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Abstract 
Background: The cytotoxicity of radiotherapy and chemotherapy can be enhanced by 
modulating DNA repair. PARP is a family of enzymes required for an efficient base-excision 
repair of DNA single-strand breaks and inhibition of PARP can prevent the repair of these 
lesions. The current study investigates the trimodal combination of ABT-888, a potent 
inhibitor of PARP1-2, ionizing radiation and temozolomide(TMZ)-based chemotherapy in 
glioblastoma (GBM) cells. 
Methods: Four human GBM cell lines were treated for 5 h with 5 µM ABT-888 before being 
exposed to X-rays concurrently with TMZ at doses of 5 or 10 µM for 2 h. ABT-888’s PARP 
inhibition was measured using immunodetection of poly(ADP-ribose) (pADPr). Cell survival 
and the different cell death pathways were examined via clonogenic assay and 
morphological characterization of the cell and cell nucleus. 
Results: Combining ABT-888 with radiation yielded enhanced cell killing in all four cell lines, 
as demonstrated by a sensitizer enhancement ratio at 50% survival (SER50) ranging between 
1.12 and 1.37. Radio- and chemo-sensitization was further enhanced when ABT-888 was 
combined with both X-rays and TMZ in the O6-methylguanine-DNA-methyltransferase 
(MGMT)-methylated cell lines with a SER50 up to 1.44. This effect was also measured in one 
of the MGMT-unmethylated cell lines with a SER50 value of 1.30. Apoptosis induction by 
ABT-888, TMZ and X-rays was also considered and the effect of ABT-888 on the number of 
apoptotic cells was noticeable at later time points. In addition, this work showed that ABT-
888 mediated sensitization is replication dependent, thus demonstrating that this effect 
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might be more pronounced in tumour cells in which endogenous replication lesions are 
present in a larger proportion than in normal cells. 
Conclusions: This study suggests that ABT-888 has the clinical potential to enhance the 
current standard treatment for GBM, in combination with conventional chemo-
radiotherapy. Interestingly, our results suggest that the use of PARP inhibitors might be 
clinically significant in those patients whose tumour is MGMT-unmethylated and currently 
derive less benefit from TMZ. 
Key words: Glioblastoma, PARP inhibition, ABT-888, radiation, temozolomide. 
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1. Background 
Glioblastoma (GBM), or WHO grade IV glioma, is the most common and malignant of all 
primary brain tumours, accounting for the most years of human life lost, per patient, than 
any other form of adult cancer [1]. Despite recent advances in combined modality 
treatment with surgery, radiotherapy and temozolomide (TMZ) chemotherapy, the outlook 
for patients is bleak with a median survival of 12-14 months [2].  
The key cytotoxic and mutagenic lesion induced by TMZ is considered to be the formation of 
O6-methylguanine (O6-MeG). Transcriptional silencing of the repair protein encoded by the 
O6-methylguanine-DNA-methyltransferase (MGMT) gene allows genotoxic damage induced 
by TMZ to persist, and is predictive of treatment outcome and patient survival [3]. Only 5% 
of all DNA methylation induced by TMZ occurs at the O6 position of guanine. N7-
methylguanine and N3-methyladenine account for 60-70% and 10-20% of the total methyl 
adducts, respectively. These lesions, together with radiation induced single stranded breaks 
(SSBs), are recognised and processed by the base excision repair (BER) pathway. The enzyme 
poly(ADP-ribose) polymerase (PARP) plays a key role in BER, by binding to processed SSBs, 
and facilitating recruitment of X-ray repair cross-complementing 1 (XRCC1). XRCC1 
intervenes as a scaffold protein recruiting other DNA polymerases and DNA ligases.  
Recent data suggest that defects in the BER system may have particular impact on the 
response to both ionizing radiation and TMZ [4]. On this basis, PARP inhibition has been 
extensively explored as a potential approach to derive additional cytotoxicity from 
radiotherapy and DNA-methylating agents. 
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ABT-888 (Veliparib) is a novel, orally bioavailable, and potent PARP inhibitor developed by 
Abbott laboratories from a modification of a benzimidazole ring. ABT-888 inhibits both 
PARP-1 and PARP-2 enzymes with an inhibitory constant, Ki, of 5.2 and 2.9 nmol/l, 
respectively [5]. Preclinical pharmacokinetic studies reported oral bioavailabilty values 
between 56 to 92% and, more importantly, ABT-888’s ability to cross the blood brain barrier 
(BBB) with plasma to brain ratio of 3:1 as evaluated in tumour-bearing rats [5].  
This study investigates the sensitizing effects of ABT-888 in combination with ionizing 
radiation and TMZ on four human GBM cell lines. It is the first in vitro study to investigate 
possible synergy between these three agents, and to assess the influence of MGMT 
promoter methylation status on tumour response. 
2. Methods 
2.1 Cell culture 
Four human GBM cell lines (T98G, LN18, U87 and U251) were used in this study. T98G cells 
were provided by Mick Woodcock, Gray Institute for Radiation Oncology and Biology, 
Oxford, UK; U87 and U251 cells were obtained from the Health Protection Agency Culture 
Collections (HPACC, Wiltshire, UK) and LN18 from the American Type Culture Collection 
(ATCC, Middlesex, UK). All cell lines were confirmed Mycoplasma free before use. The cells 
were cultured as previously described in Barazzuol et al. [6].  
2.2 MGMT Western blot analysis 
Cell lysates were obtained by repeatedly syringe the cells up and down with a 21G needle in 
lysis buffer (20 mM Tris, 100 mM HCl, 5 mM EDTA, 1 mM EGTA, 5 mM β-mercaptoethanol; 
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pH 7.5; Sigma-Aldrich, Dorset, UK). The cell lysate was centrifuged at 13,000 x g for 20 min 
at 4  C. Protein concentration was measured using Thermo Scientific Bradford assay kit 
(Thermo Scientific, Nortumberland, UK .  amples ere then boiled at 99  C for 5 min. Protein 
lysates (30 µg) were then run on a Bio-Rad precast gel (Bio-Rad, Hertfordshire, UK) at a 
constant voltage of 125 V for 1.5 h. Wet transfer was done using a PVDF membrane for 30 
min on the Bio-Rad Trans-Blot Turbo transfer system. After blocking in 5% not fat semi-
skimmed milk and TBST (20 mM Tris-HCl, 150 Mm NaCl, 0.1% Tween 20; pH 7.6) for 5 h, the 
membrane was incubated at 4  C overnight with primary antibody against MGMT (2739; Cell 
Signaling Technology, Danvers, US) diluted at 1:250 in TBST. Afterwards the membrane was 
washed 3 times in TBST for 5 min and then incubated for 1.5 h with horseradish peroxidase-
conjugated goat anti-rabbit secondary antibody diluted at 1:2000 in TBST. The membrane 
was then rewashed 3 times in TBST for 5 min before detecting MGMT expression using the 
Bio-Rad Immun-Star chemiluminescent kit. 
2.3 Drug treatment 
TMZ was provided by Fluka (Sigma-Aldrich, Dorset, UK) and reconstituted in 
dimethylsulfoxide (DMSO) to a final concentration not exceeding 0.1% (at this 
concentration, DMSO alone had no effect on cell viability). TMZ was administered at 
different concentrations and exposure times according to the type of experiment. For 
single-agent TMZ cytotoxicity, cells were exposed continuously to increasing concentrations 
of TMZ according to the MGMT status. For combined TMZ, ABT-888 and radiation, TMZ was 
administered in 5 μM for the MGMT-methylated cells and 10 μM for the MGMT-
unmethylated cells for a total exposure time of 2 h, including 1 h before irradiation. After 2 
h with TMZ, the medium was replaced.  
     7 
 
ABT-888 was supplied by Enzo Life Sciences (Farmingdale, US) and reconstituted in Milli-Q 
water. For single ABT-888 cytotoxicity, cells were incubated continuously with increasing 
concentrations of ABT-888 from 0.002 to 50 μM. For the combined experiments with TMZ 
and radiation, ABT-888 was used at 5 μM and administered for 5 h prior to TMZ treatment 
and irradiation (2 h exposure time for TMZ). 
2.4 Irradiation 
X-ray irradiation was performed using a Gulmay machine operating at 250 kVp with a dose 
rate of 0.65 Gy/min (Royal Surrey County Hospital, Guildford, UK). Cells were grown in 6- 
well plates and incubated for 5 h before irradiation. Cells were then exposed at room 
temperature to doses between 1 to 6 Gy. 
2.5 Clonogenic survival assay 
Clonogenic assay was used to evaluate single drug cytotoxicity (TMZ and ABT-888) and 
combined treatments (ABT-888, TMZ and X-rays). Cells were grown in 6-well plates and 
after treatment incubated for up to 14 days. Colonies were fixed with 50% ethanol in PBS 
and then stained with 5% crystal violet in PBS (Sigma-Aldrich, Dorset, UK). The colonies with 
more than 50 cells were counted and the survival fractions were determined taking into 
consideration the plating efficiency for all treatment modalities based on three separate 
experiments. 
2.6 pADPr immunofluorescence quantification 
Cells were grown in polystyrene dishes at a concentration of 5 × 105 cells/ml, and pre-
treated ith 5 μM ABT-888 for 2 h before treatment with 20 mM hydrogen peroxide (H2O2) 
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for 10 min ith or ithout 5 μM ABT-888. Cells were then washed with ice-cold PBS and 
fixed with ice-cold methanol/acetone (50:50) for 5 min. Samples were then washed twice 
with ice-cold PBS and incubated with 1% BSA in PBS for 30 min, before being probed for 
pADPr adding an anty-pADPr antibody (ab14459; Abcam, Cambridge, UK) at a dilution of 
1:400 in 1% BSA in PBS for 1 h at room temperature. Cells were then washed three times 
with PBS before adding FITC-conjugated goat anti-mouse IgG secondary antibody (Millipore, 
Watford, UK) at a dilution of 1:400 in 1% BSA in PBS for 1 h protected from light. Cells were 
 ashed three times ith PB  before adding 2.5 μg/ml 4’,6-diamidino-2-phenylindole 
dilactate (DAPI; Invitrogen, Oregon, US) in PBS for 1 min. Finally, round coverslips were 
mounted ith 10 μl of ProLong Gold anti-fade reagent (Invitrogen, Oregon, US). Samples 
were analysed using the microscope described in a separate paper [7] at ×40 magnification. 
Image processing was performed using ImageJ (v1.44p, National Institutes of Health, 
Bethesda, US) and the pADPr signal intensity was measured as the mean gray value within 
selected regions of interest (ROI) corresponding to the relative DAPI-stained nuclei.  
2.7 Cell death analysis 
Cells were treated as described above and collected at different time points after irradiation 
(1, 5, 10, 24, 48 and 72 h for 3 Gy; and, 24 and 48 h for 2 and 4 Gy) and fixed in 1% 
formaldehyde (Sigma-Aldrich, Dorset, UK). Samples were stained with 10 μg/ml acridine 
orange and 8.3 μg/ml Hoechst 33342 (Invitrogen, Oregon, US). The morphological 
characterization of cell death included apoptosis, necrosis and mitotic catastrophe 
(Additional File 1). Between 200 and 400 cells were scored for each sample. 
2.8 Statistical analysis 
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All experiments were performed in either duplicate or triplicate. The error bars represent 
the standard error among the different experiments. The sensitizer enhancement ratio (SER) 
was used to evaluate the drug-radiation interaction. Its value was estimated from fitting to 
the Linear-Quadratic (LQ )model as follows: 
 ERx   
dx  no drug 
dx  drug 
 
where dx%(no drug) is the radiation dose (Gy) required to produce x% cell survival without 
drug and dx%(drug) in presence of drug (i.e. TMZ and/or ABT-888). SER was calculated at 
doses related to surviving fractions of 37 and 50%. 
Statistical significance was determined using a two-sample t-test and a p value less than 
0.05 was considered significant. 
3. Results 
3.1 Cell sensitivity to TMZ and ABT-888 
Our panel of four GBM cell showed heterogeneous MGMT protein expression. LN18 and 
T98G showed high expression levels of MGMT; whereas, the other two cell lines, U87 and 
U251, had undetectable levels of MGMT (Figure 1). The EC50 values for TMZ ranged between 
9.64 (U87) to 346.65 μM (LN18) (Figure 2). MGMT-unmethylated LN18 and T98G cell lines 
showed the highest resistance to TMZ, confirming that MGMT is an important predictive 
factor of response to TMZ [3]. 
The EC50 values for ABT-888 were 19.64, 22.02, 6.44 and 21.9 μM for LN18, T98G, U87 and 
U251, respectively (Figure 3). No correlation was observed between MGMT methylation 
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status and ABT-888 sensitivity. However, MGMT-methylated, p53 wild type U87 cells were 
significantly more sensitive to prolonged exposure of ABT-888 than the other cell lines.  
A concentration of 5 μM ABT-888 was then used in the subsequent experiments. This 
concentration of ABT-888 for an exposure time of 5 h did not yield considerable cellular 
cytotoxicity (Figure 4). 
3.2 Evaluation of pADPr synthesis in the presence of ABT-888 
Upon DNA damage, PARP catalyzes the formation of the polymer pADPr, therefore PARP 
activity was assessed by measuring the level of pADPr. Under normal conditions, all cells 
displayed low basal levels of pADPr. Treatment with 20 mM H2O2 induced PARP activation as 
demonstrated by a rapid increase of pADPr synthesis. In contrast, cells treated ith 5 μM 
ABT-888 for 2 h before exposure to H2O2 showed no significant difference in pADPr as 
compared to basal levels (Figure 5). These data validated that the dose of ABT-888 chosen 
was suitable to inhibit PARP activity. 
3.3 Clonogenic survival after treatment with X-rays, TMZ and ABT-888 
Cell survival was investigated after combined treatment with ABT-888, TMZ and X-rays 
(Figure 6). No significant interaction between X-rays and TMZ for the doses chosen (5 and 10 
μM for the MGMT-methylated and -unmethylated cell lines, respectively) could be observed 
in all four cell lines. The SER50 and SER37 values were near unity and the p values calculated 
at the dose of 50% and 37% survival were all greater than 0.24 (Table 1). 
The combination of X-rays and ABT-888 led to a substantial radiosensitizing effect with SER50 
ranging between 1.13 and 1.37, and SER37 between 1.12 and 1.31. This was also 
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accompanied by an increase in α parameter of the LQ model (Table 1 . The highest 
radiosensitization was found in LN18 and U251 cell lines, as demonstrated by SER50 values 
above 1.28. T98G and U87 cell lines displayed only a modest effect of ABT-888 on the 
radiation survival curve (p = 0.16-0.24 Figures 6b and 6c). Importantly, the radiosensitizing 
effect of ABT-888 was independent of the MGMT methylation status.  
The triple combination of X-rays, TMZ and ABT-888 was more effective than single agents in 
all four cell lines and appeared to be more pronounced in the two MGMT-methylated cell 
lines. Higher levels of ABT-888-mediated sensitization to X-rays and TMZ were observed in 
both U87 and U251 cell lines with SER50 of 1.30 and 1.44, respectively. Further sensitization 
was also observed in the MGMT-unmethylated T98G cell line with SER50 of 1.30 for all three 
agents compared to 1.16 with the dual combination of X-rays and ABT-888. However, no 
additional enhancement was observed with LN18 cells after trimodal treatment compared 
to X-rays and ABT-888 (SER50 of 1.28 compared to SER50 of 1.25; Table 1). 
3.4 Induction of apoptosis by X-rays, TMZ and ABT-888 
Time-course measurements of apoptosis were undertaken after exposure to a radiation 
dose of 3 Gy in combination with TMZ and ABT-888 (Figure 7). The induction of apoptosis 
increased with time reaching a maximum level at 72 h in the range of 11.21 to 14.28% and 
11.77 to 13.24% for LN18 and U87 cells, respectively (p < 0.03 Figure 7a; p = 0.22 Figure 7b).  
In MGMT-unmethylated LN18 cells, a single early apoptotic peak was observed 5 h after 
treatment with X-rays, TMZ and ABT-888, as demonstrated by the amount of apoptotic cells 
that was greater (8.27%) than with X-rays alone (5.89%). However, this disproportion was 
not statistically significant (p = 0.23 Figure 7a). This peak was not seen in the MGMT-
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methylated U87 cells. Apoptotic responses for U87 cells were very similar for the different 
treatment combinations (p > 0.05 Figure 7a). 
In addition, dose-response measurements were performed at 24 and 48 h after irradiation 
with 2, 3 and 4 Gy (Figure 7). Both LN18 and U87 cells showed a dose-dependent increase in 
radiation-induced apoptotic cells. At 48 h, the trimodal treatment seemed to be more 
effective than single modalities. In particular, in U87 there was a significant difference in 
apoptosis after treatment with 4 Gy, TMZ and ABT-888 as compared with radiation alone (p 
< 0.04 Figure 7f).  
The sensitizing effect of ABT-888 to TMZ and X-rays may involve other cell death pathways 
distinct from apoptosis. Therefore, mitotic catastrophe and necrosis were evaluated at 72 h 
after treatment with 3 Gy X-rays, TMZ and ABT-888. A minimal amount of cells (< 3%) 
undergoing mitotic catastrophe and necrosis was seen in both LN18 and U87 cells for all 
treatment combinations (data not shown). 
4. Discussion 
PARP inhibition is a promising mechanism for enhancing efficacy of chemoradiation therapy. 
A number of PARP inhibitors are currently being assessed in clinical trials, including ABT-888 
for which six phase I-II clinical trials exist in patients with brain or central nervous system 
(CNS) tumours [8]. 
To date, only one preclinical study has looked at the trimodal combination of PARP inhibitor 
ABT-888 with TMZ and X-rays in GBM xenografts [9]. The present in vitro study suggests that 
ABT-888 enhances the effects of radiation. A further sensitization has also been shown 
when ABT-888 was added to both TMZ and X-rays. Although the maximum enhancement in 
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cell killing was obtained in MGMT-methylated cell lines, MGMT expression did not prevent 
ABT-888-mediated sensitization. This study also indicates that PARP inhibition has an effect 
on the apoptotic cell death pathway. 
4.1 ABT-888 is a potent inhibitor of PARP 
Our study confirmed ABT-888’s favourable pharmacokinetic profile and effective 
attenuation of pADPr formation at a non-cytotoxic concentration of 5 μM in all four GBM 
cell lines. These results concur with previously reported data by Albert et al. [10] on H460 
lung carcinoma cells and Horton et al. [11] on leukaemia cells, in which an optimal dose of 5 
μM ABT-888 was determined for in vitro models. Importantly, phase 0-I clinical trials have 
established the achievable area under the plasma concentration time curve for ABT-888 to 
be 1.46 µM at an initial dose of 10 mg administered orally twice a day (BID) showing that 
µM concentrations are clinically achievable [12, 13]. 
The EC50 values for ABT-888 did not show strong variations among the cell lines, except for 
the MGMT-methylated, p53 wild-type U87 cell line (EC50 = 6.44 μM . It ould be of interest 
to elucidate the relationship between PARP and p53 as all the other cell lines (LN18, T98G 
and U87) were mutant for p53. Previous reports suggest that PARP-1 is a critical regulator of 
the p53 response to DNA damage [14, 15]. This observation might be relevant to the clinical 
treatment of GBM as about a third of GBMs have p53 mutations [16]. 
4.2 ABT-888 enhances radiation response regardless of the MGMT status 
The results demonstrated that exposure to 5 μM ABT-888 for 5 h before irradiation resulted 
in significant radiosensitization of all four cell lines (SER50 = 1.12-1.37), regardless of the 
MGMT methylation status (Figure 6). The radiosensitizing effect of ABT-888 seemed to be 
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inversely related to the cell population doubling time. Indeed, this effect was more 
pronounced in LN18 and U251 cells with SER50 of 1.28 and 1.37, respectively, and doubling 
times of 24 h. This is relevant in the case of brain tumours as the surrounding normal tissue 
is composed of cells which proliferate slowly or not at all [17-19]. 
Consistent with the current study, Albert et al. [10] found that 6 h exposure to 5 μM ABT-
888 sensitizes lung cancer H460 cells to radiation with a SER25 of 1.27. This was also 
accompanied by a delay in the resolution of γ-H2AX foci at 6 h after irradiation. Similarly, 
Efimova et al. [20] noted that ABT-888 markedly enhances persistence of γ-H2AX foci in 
breast cancer cells up to 24 h after irradiation. Liu et al. [21] also showed that ABT-888 
impairs the resolution of DSBs remaining at 24 h in the malignant prostate cancer 22RV1 cell 
line. Altogether, these data suggest that the radiosensitizing effect of ABT-888 is likely to be 
the consequence of an interaction between unrepaired SSBs and collapsed DNA replication 
forks [17]. Collapsed replication forks are recognized by the cell cycle checkpoint system 
which in turn initiates cell cycle arrest, DNA repair or cell death [4]. 
In vivo, one study using an HCT-116 colon model reported that ABT-888 is an effective radio-
sensitizer [5]. However, Clarke et al. [9] reported no effect of ABT-888 addition on survival 
relative to radiotherapy alone on two primary GBM xenografts. 
4.3 ABT-888 further enhances response to TMZ plus X-rays in MGMT-methylated cell lines 
Stratification of clinical treatment response by MGMT-methylation status demonstrates 
poorer outcomes for patients with MGMT-unmethylated tumours. An agent capable of 
enhancing radiation response in this group would be a valuable new treatment. Our study 
suggests that trimodal treatment with ABT-888, TMZ and X-rays seems to mostly enhance 
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cell killing in the MGMT-methylated U87 and U251 cell lines (Figure 6). The relative SER50 
increased from 1.13 and 1.37 with ABT-888 plus X-rays to 1.3 and 1.44 with ABT-888, TMZ 
and X-rays for U87 and U251 cell lines, respectively. These SER values lie in the range of 
those obtained with platinum- and taxane-based chemotherapy for different tumour types 
and end points [22, 23].  
An increase in SER50 was also noted in the MGMT-unmethylated T98G cells. This observation 
suggests that the MGMT methylation status is not an absolute predictor of response to 
trimodal treatment. However, there is disagreement in the literature on whether ABT-888-
mediated sensitization to TMZ is independent of the MGMT. Palma et al. [24] reported that 
neither MGMT nor mismatch repair (MMR) precluded sensitivity to ABT-888 plus TMZ in 
several tumour types. Likewise, Horton et al. [11] suggested that ABT-888 chemo-
potentiation in leukaemia and colon cancer cells might not depend on MGMT activity. 
However, the authors acknowledged that ABT-888 was less effective in the presence of 
elevated MGMT levels. In contrast, Clarke et al. [9] showed that not all GBM tumours 
respond equally to ABT-888 plus TMZ, suggesting that ABT-888 may not overcome tumour 
resistance to TMZ.  
Furthermore, it would be of interest to explore different treatment schedules, in particular a 
different duration of ABT-888 and TMZ exposure before irradiation, and whether TMZ might 
further sensitize the cells to radiation. To date, a growing number of preclinical studies have 
looked at the effects of TMZ on the radiosensitivity of GBM cell lines reporting opposing 
results. While some studies support a synergistic effect between concurrent TMZ and 
radiation in favour of radiosensitization [25-28], other papers reported independent cell 
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killing [29-32]. It is likely that the optimal schedule of drug administration for TMZ-mediated 
radiosensitization is the one that will also result in an increased efficiency of ABT-888. 
4.4 ABT-888 has an effect on apoptotic response 
Apoptosis is an energy dependent form of cell death, and as such, it requires adenosine-5'-
triphosphate (ATP). The principal substrate of PARP is nicotinamide adenine dinucleotide 
(NAD+), which is required to catalyse pADPr in the presence of DNA damage. In turn, a 
reduction in NAD+ leads to a depletion of ATP. By preventing ATP loss, inhibition of PARP 
should enhance the apoptotic response to genotoxic damage. Our results confirm that the 
combination of ABT-888 with either radiation or radiation plus TMZ had an effect on the 
apoptotic response, noticeable at later time points after treatment (Figure 7).  
Similarly, Albert et al. [9] assessed apoptosis after treatment ith 5 μM ABT-888 and 
radiation on a lung cancer H460 cell line, reporting a 2.8-fold increase in apoptosis 
compared to control. Additionally, in vivo TUNEL analysis on sections of H460 tumour 
models showed a 65% increase in apoptosis when ABT-888 was added to radiotherapy. In a 
separate study, Liu et al. [33] sho ed that 5 μM ABT-888 co-treatment with the DNA 
alkylating agent N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) induced activation of 
caspase-9 and caspase-3 and increased apoptosis in cervical cancer HeLa cells by preventing 
ATP loss. Nowsheen et al. [34] reported a significant increase in apoptosis when head and 
neck cancer cells were treated with cetuximab and ABT-888. They hypothesized that 
apoptosis by PARP inhibition was due to intracellular stress signals, which resulted in the 
activation of the apoptotic intrinsic pathway. More recently, Huehls et al. [35] reported that 
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ABT-888 promoted apoptosis in ovarian cancer cells treated with 5-fluorodeoxyuridine 
(FdUrd) but not with 5-fluorouracil (5-FU). 
5. Conclusions 
In summary, this study showed that modulating DNA repair by selectively inhibiting PARP is 
a potential therapeutic approach to enhance standard treatment in patients with GBM. The 
most attractive use of PARP inhibitors might be in those patients whose tumour is MGMT-
unmethylated and currently derive less benefit from chemo-radiotherapy.  
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Figure Legends 
Figure 1 
Western blot analysis showing the MGMT protein levels and the protein loading control in a 
panel of four GBM cell lines (LN18, T98G, U87 and U251). 
Figure 2 
Cell survival curves of MGMT-unmethylated cell lines, LN18 (a) and T98G (b), and MGMT-
methylated cell lines, U87 (c) and U251 (d). Cells were exposed continuously to increasing 
concentrations of TMZ alone. The data were fitted with the Hill equation (solid line) in order 
to estimate the EC50 values. Error bars indicate the standard error of at least three 
independent experiments. 
Figure 3 
Cell survival curves of MGMT-unmethylated cell lines, LN18 (a) and T98G (b), and MGMT-
methylated cell lines, U87 (c) and U251 (d). Cells were exposed continuously to increasing 
concentrations of ABT-888 alone (0.002-10 µM). The data were fitted with the Hill equation 
(solid line) in order to estimate the EC50 values. Error bars indicate the standard error of at 
least three independent experiments. 
Figure 4 
Plating efficiency (PE) for cells incubated for 5 h with or without 5 μM ABT-888. No 
significant difference in survival relative to untreated cells was observed (p > 0.8). 
Figure 5 
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(a) Immunofluorescence detection of pADPr in GBM cells exposed to 20 mM H2O2 with or 
 ithout 5 μM ABT-888; scale bar at bottom right   10 μm. (b) Fluorescence intensity 
quantification of the pADPr signal in Figure 3 estimated using ImageJ (v1.44p, National 
Institutes of Health, Bethesda, US). Error bars indicate the standard error among 100 cell 
nuclei. 
Figure 6 
Cell survival curves of MGMT-unmethylated LN18 (a) and T98G cells (b), and MGMT-
methylated U87 (c) and U251 cells (d). Cells were treated ith 5 μM ABT-888 for 5 h before 
being exposed to either 5 (c ,d) or 10 (a, b  μM TMZ for 2 h, including 1 h before and 1 h 
after irradiation. Symbols represent mean ± standard error of at least three independent 
experiments. 
Figure 7 
Percentages of apoptotic cells in MGMT-unmethylated LN18 (a) and MGMT-methylated U87 
cells (b  up to 72 h after irradiation. Cells ere exposed for 5 h to 5 μM ABT-888 before 
being treated ith 5 (b  or 10 (a  μM TMZ for 2 h and irradiated ith 3 Gy X-rays. Dose-
response percentages of apoptotic cells in MGMT-unmethylated LN18 (c, d) and MGMT-
methylated U87 cells (e, f). Cells were exposed to 2, 3 and 4 Gy X-rays and fixed at 24 and 48 
h after irradiation. Error bars indicate the standard error of two independent experiments. 
Please note the scale change on the Y-axis of the graphs. P values relatively to the control 
are also shown.  
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Table 1 
Radiobiological parameter values 
Mean values of α, β,  ER50 and SER37 (including p values) of MGMT-unmethylated LN18 and T98G cells, and of MGMT-methylated U87 and 
U251 cells, estimated by fitting the cell survival to the LQ model.  
Treatment 
LN18 T98G U87 U251 
α (Gy-1) β (Gy-2) SER50 (p) SER37 (p) α (Gy-1) β (Gy-2) SER50 (p) SER37 (p) α (Gy
-1) β (Gy-2) SER50 (p) SER37 (p) α (Gy
-1) β (Gy-2) SER50 (p) SER37 (p) 
X-rays 0.08 ± 0.02 0.04 ± 0.01 - - 0.04 ± 0.02 0.05 ± 0.01 - - 0.15 ± 0.04 0.04 ± 0.01 - - 0.01 ± 0.02 0.06 ± 0.01 - - 
X-rays + 5/10 µM TMZ 0.13 ± 0.02 0.04 ± 0.01 1.08 (0.32) 1.06 (0.36) 0.02 ± 0.01 0.05 ± 0.01 0.95 (0.52) 0.96 (0.50) 0.12 ± 0.05 0.05 ± 0.01 0.99 (0.93) 1.01(0.92) 0.04 ± 0.03 0.06 ± 0.01 1.08 (0.24) 1.06 (0.30) 
X-rays + 5 µM ABT-888 0.18 ± 0.02 0.04 ± 0.01 1.28 (0.01) 1.23 (0.01) 0.12 ± 0.02 0.04 ± 0.01 1.16 (0.25) 1.12 (0.20) 0.21 ± 0.02 0.04 ± 0.01 1.13 (0.16) 1.12 (0.17) 0.12 ± 0.02 0.07 ± 0.01 
1.37 
(0.002) 
1.31 
(0.002) 
X-rays + 5 µM ABT-888 
+ 5/10 µM TMZ 
0.16 ± 0.01 0.05 ± 0.01 1.25 (0.02) 1.21 (0.01) 0.15 ± 0.01 0.04 ± 0.01 1.30 (0.03) 1.24 (0.01) 0.33 ± 0.02 0.02 ± 0.01 1.30 (0.03) 1.24 (0.04) 0.20 ± 0.01 0.05 ± 0.01 
1.44 
(0.003) 
1.35 
(0.001) 
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Additional files 
Additional file 1 
Morphological classification of cells after dual fluorescent staining with acridine orange (AO) 
and Hoechst 33342 (HO). Representative photographs of apoptosis (a), mitotic catastrophe 
(b) and necrosis (c). 
 
